SCHEMBL14082709

SCHEMBL14082709

Cc1cc2nc(CNC(C)(C)C)[nH]c2cc1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 5/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ MAPT P10636 2/20 0.58
▸ ATM Q13315 2/20 0.58
▸ PSMD14 O00487 1/20 0.58
▸ MMP2 P08253 1/20 0.58
▸ TDP1 Q9NUW8 1/20 0.58
▸ PDE10A Q9Y233 1/20 0.47
▸ FABP6 P51161 1/20 0.46
▸ KDM4E B2RXH2 3/20 0.45
▸ CACNA1B Q00975 1/20 0.45
▸ APBA1 Q02410 1/20 0.45
▸ MCL1 Q07820 1/20 0.45
▸ F10 P00742 1/20 0.44
▸ METAP1 P53582 2/20 0.40
▸ METAP2 P50579 1/20 0.40
▸ CBFB Q13951 1/20 0.40
▸ HRH4 Q9H3N8 1/20 0.39
▸ GAA P10253 2/20 0.39
▸ HTT P42858 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16188974 0.81 KMT2A (0.64) KMT2AMEN1MAPTATMPSMD14
SCHEMBL14107752 0.79 KMT2A (0.60) KMT2AMEN1MAPTATMPSMD14
SCHEMBL13950568 0.77 TDP1 (0.44) TDP1KDM4EHRH4GAAHTT
SCHEMBL30701865 0.77 KMT2A (0.72) KMT2AMEN1MAPTATMPSMD14
SCHEMBL7853107 0.77 KMT2A (0.72) KMT2AMEN1MAPTATMPSMD14
SCHEMBL5897142 0.76 KMT2A (0.57) KMT2AMEN1MAPTATMPSMD14
SCHEMBL8845396 0.75 KMT2A (0.70) KMT2AMEN1MAPTATMPSMD14
SCHEMBL8260645 0.75 PKM (0.66) MAPTKDM4EGAAPOLBALDH1A1
Hydrochloric Acid SCHEMBL10511632 0.75 MAPT (0.51) KMT2AMEN1MAPTATMPSMD14
SCHEMBL24027323 0.75 PKM (0.39) KMT2AMEN1MAPTKDM4EGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080194545-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE TRIUS THERAPEUTICS (US) 2008-08-14 — — US disclosed
US-20080194545-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE TRIUS THERAPEUTICS (US) 2008-08-14 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194545-A1 ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE ABCB11, FPR1, C5 KMT2A 4781/4885MEN1 1366/4885MAPT 3255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback